Prosight Management, LP Metacrine, Inc. Transaction History

Prosight Management, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$0.64 - $3.83 $732,821 - $4.39 Million	-1,145,034 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$2.61 - $3.84 $720,234 - $1.06 Million	275,952 Added 31.75%	1,145,034 $3.93 Million
Q2 2021 Aug 13, 2021	BUY	$3.37 - $5.73 $1.9 Million - $3.24 Million	564,597 Added 185.43%	869,082 $3.3 Million
Q1 2021 May 14, 2021	SELL	$6.2 - $11.0 $1.6 Million - $2.85 Million	-258,818 Reduced 45.95%	304,485 $1.89 Million
Q4 2020 Feb 12, 2021	BUY	$7.75 - $11.42 $344,929 - $508,269	44,507 Added 8.58%	563,303 $4.43 Million

Q3 2020 Nov 13, 2020	BUY	$9.38 - $11.76 $4.87 Million - $6.1 Million	518,796 New	518,796 $5.3 Million

Ticker MTCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,569,500
Description
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Get notified when there are updates to the investment portfolio of Prosight Management, LP, based on Form 13F filings with the SEC.

Stay updated on Prosight Management, LP with notifications on news.